Evidence map›Paper›PMID 40790245›Full record

ArticleInfectious diseases of poverty2025

Global, regional, and national burdens of pertussis among adults: a systematic analysis of age-specific trends using Global Burden of Diseases 2021 data.

Kangguo Li, Jiadong Wu, Ruixin Zhang, Yulun Xie, Zecheng Zhou, Qi Yin, Qi Chen, Jia Rui, Xuhua Guan, Zeyu Zhao and 1 more

Abstract read
In one paragraph

Article in Infectious diseases of poverty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kangguo LiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China.
Jiadong WuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China.
Ruixin ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China.
Yulun XieState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China.
Zecheng ZhouState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China.
Qi YinState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China.
Qi ChenDepartment of Acute Infectious Disease Control, Institute of Infectious Disease Prevention and Control, Hubei Provincial Center for Disease Control and Prevention, Wuhan, China.
Jia RuiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China. ruijia5345@163.com.
Xuhua GuanDepartment of Acute Infectious Disease Control, Institute of Infectious Disease Prevention and Control, Hubei Provincial Center for Disease Control and Prevention, Wuhan, China. guanxh9999@163.com.
Zeyu ZhaoState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China. 381597586@qq.com.
Tianmu ChenState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China. chentianmu@xmu.edu.cn.ORCID http://orcid.org/0000-0003-0710-5086

Funding

Postdoctoral Fellowship Program of China GZC20240890Scientific Research Foundation of State Key Laboratory of Vaccines for Infectious Disease, Xiang An Biomedicine Laboratory 2024XAKJ0100003
6 · The paper itself

Abstract

backgroundDespite the high coverage of childhood vaccination, pertussis remains a significant global health challenge, with increasing adult cases attributed to waning immunity and enhanced diagnostic capability. This study quantified the global burden of pertussis in adults from 1990 to 2021 and evaluated the impact of the COVID-19 pandemic on disease trends.

methodsUsing data from the Global Burden of Disease Study 2021, we assessed pertussis incidence and disability-adjusted life years (DALYs) in adults, stratified by age, sex, sociodemographic factors, and geographic regions. Temporal trends were analysed using joinpoint regression to detect significant changes and calculate the average annual percentage change (AAPC). An exponential smoothing state-space model with hierarchical forecast reconciliation was used to estimate the impact of the COVID-19 pandemic on pertussis burden.

resultsGlobally, the incidence rate of adult pertussis declined from 17.44 per 100,000 population in 1990 to 9.00 per 100,000 in 2019, and fell sharply to 2.70 per 100,000 by 2021. DALYs rates followed a similar trend. The burden was consistently highest in low Socio-demographic Index (SDI) countries, where the 2019 incidence rate was over four times that of high SDI countries (18.59 vs. 3.96 per 100,000). Between 1990 and 2019, incidence numbers increased in low SDI countries [AAPC: 0.63%; 95% confidence interval: 0.36%, 0.91%] and in older adults (AAPC > 0), despite falling incidence rates. From 2009 to 2019, incidence rates increased in 84 countries. During the COVID-19 pandemic, estimates based on the model indicated a 58.41% reduction in incidence and a 50.34% decrease in DALYs.

conclusionsAlthough the global incidence of adult pertussis has declined over the past three decades, a resurgence from 2009 to 2019, particularly in low-income regions and specific age groups, underscores the persistent challenges. The sharp decline during the COVID-19 pandemic highlights the importance of public health and social measures. These findings emphasise the need for targeted vaccination strategies and sustained surveillance to address regional disparities and prevent the resurgence of the disease.

Indexed as

COVID-19Global Burden of DiseaseWhooping CoughAdolescentAdultAgedAge FactorsDisability-Adjusted Life YearsFemaleGlobal HealthHumansIncidenceMaleMiddle AgedSARS-CoV-2Young AdultAdultDisability-adjusted life yearsIncidencePertussisResurgence

Identifiers

PMID40790245
PMCPMC12337552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.